OncoStem Diagnostics

Executive Summary

OncoStem Diagnostics is a pioneering Indian biotech company specializing in AI-driven, biomarker-based prognostic tests for early-stage breast cancer. Their flagship product, CanAssist Breast, predicts the five-year recurrence risk using FFPE tumor tissue and a proprietary algorithm. This test enables oncologists to personalize treatment decisions, potentially sparing low-risk patients from unnecessary chemotherapy and its associated side effects. By integrating artificial intelligence with established biomarkers, OncoStem provides a cost-effective and accessible solution tailored to the Indian healthcare ecosystem, where breast cancer incidence is rising and treatment costs are a significant concern. The company has achieved commercial traction with over 10,000 tests sold and has garnered interest from international markets, positioning itself as a key player in precision oncology in emerging economies. Looking ahead, OncoStem is focused on expanding its test’s clinical evidence base through multicenter studies, securing reimbursement from insurance providers, and pursuing regulatory approvals in Southeast Asian and Middle Eastern countries. The company also aims to develop additional prognostic tests for other solid tumors, leveraging its proprietary platform. With a strong scientific foundation, experienced leadership, and a clear unmet need, OncoStem is well-positioned for growth, though it faces challenges including competition from established molecular tests and the need for sustained funding to scale operations and build commercial infrastructure.

Upcoming Catalysts (preview)

• Q3 2026Publication of prospective validation study for CanAssist Breast in peer-reviewed journal80% success
• Q4 2026Strategic partnership with a major Indian hospital chain for large-scale adoption65% success
• Q1 2027Regulatory approval for CanAssist Breast in a new market (e.g., Indonesia or Saudi Arabia)55% success